Bobak R. Azamian - 15 Mar 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
President/CEO and Board Chair, Director
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
15 Mar 2026
Net transactions value
$0
Form type
4
Filing time
17 Mar 2026, 16:24:44 UTC
Previous filing
09 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Azamian Bobak R. President/CEO and Board Chair, Director C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE /s/ Jeffrey Farrow, Attorney-in-Fact 17 Mar 2026 0001827672

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +66,274 +3787% 68,024 15 Mar 2026 Direct F1
holding TARS Common Stock 857,991 15 Mar 2026 By the Bobak Azamian Living Trust established April 16, 2018 F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise -11,300 -100% $0.000000* 0 15 Mar 2026 Common Stock 11,300 Direct F3, F4
transaction TARS Restricted Stock Units Options Exercise -16,975 -50% $0.000000* 16,975 15 Mar 2026 Common Stock 16,975 Direct F3, F5
transaction TARS Restricted Stock Units Options Exercise -23,121 -33% $0.000000* 46,243 15 Mar 2026 Common Stock 23,121 Direct F3, F6
transaction TARS Restricted Stock Units Options Exercise -14,878 -25% $0.000000* 44,634 15 Mar 2026 Common Stock 14,878 Direct F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
F2 The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
F3 Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.
F4 RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.
F5 RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
F6 RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
F7 RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.